DV
Dividend Vision

NMRA — Neumora Therapeutics, Inc.

Neumora Therapeutics, Inc. (NMRA)

Total return is -90.6% over the past 2.9 years, 169.5 points behind SPY at 78.9%. Its deepest 1-year drawdown was 74.5%.

Neumora Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases, with its most advanced program being navacaprant (NMRA-140), a kappa opioid receptor antagonist in phase 3 clinical trials for major depressive disorder, along with several earlier-stage programs targeting conditions including dementia-related agitation, schizophrenia, Parkinson's Disease, and obesity. The company does not currently distribute dividends or other cash payments to shareholders. Neumora is suited to investors seeking exposure to early-stage biotech development with no current income component, as returns would depend entirely on clinical trial success and future commercialization milestones.

NMRA key facts

Asset type
Stock
Asset class
Equity
Inception date
09/14/2023
Last close
$1.60
Market cap
$299,234,048
Average volume
1165500.0
Beta
2.773
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.32